KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts
KRASmt and NRASmt are seen in 49% and 4% of mCRC, respectively. No clinically relevant differences were observed between different RASmt. KRASmt is a common subgroup for which the outcome hopefully can be improved with newly developed drugs.
Authors
- Raija Ristamäki (ORCID: https://orcid.org/0000-0001-6817-3045)
- Tobias Sjöblom (ORCID: https://orcid.org/0000-0001-6668-4140)
- Päivi Halonen (ORCID: https://orcid.org/0000-0002-9760-0840)
- Halfdan Sørbye (ORCID: https://orcid.org/0000-0002-7132-6214)
- Eetu Heervä (ORCID: https://orcid.org/0000-0002-6134-1170)
- Annika Ålgars (ORCID: https://orcid.org/0000-0002-9841-1881)
- Annamarja Lamminmäki (ORCID: https://orcid.org/0000-0001-7664-4468)
- Aki Uutela (ORCID: https://orcid.org/0000-0003-1324-5894)
- Hanna Stedt
- Soili Kytölä (ORCID: https://orcid.org/0000-0002-4477-0942)
- Markus J. Mäkinen (ORCID: https://orcid.org/0000-0002-9200-4118)
- Ari Ristimäki (ORCID: https://orcid.org/0000-0002-5373-9234)
- Raija Kallio (ORCID: https://orcid.org/0000-0002-5912-496X)
- Emerik Österlund (ORCID: https://orcid.org/0000-0003-0973-6332)
- Kaisa Lehtomäki (ORCID: https://orcid.org/0000-0002-2994-1459)
- Bengt Glimelius (ORCID: https://orcid.org/0000-0002-5440-791X)
- Pia J. Osterlund (ORCID: https://orcid.org/0000-0002-7124-3515)
- Tapio Salminen (ORCID: https://orcid.org/0000-0003-4116-2260)
- Luís Nunes (ORCID: https://orcid.org/0000-0002-3391-1607)
- Per Pfeiffer (ORCID: https://orcid.org/0000-0002-2925-0586)
- Helena Isoniemi (ORCID: https://orcid.org/0000-0001-6184-3405)
- Arno Nordin (ORCID: https://orcid.org/0000-0002-5446-0972)
- Timo Muhonen
- Jari Sundström (ORCID: https://orcid.org/0000-0002-0800-970X)
- Joel Kontiainen
- Sonja Aho (ORCID: https://orcid.org/0000-0002-4965-5580)
- Lasse Nieminen
Institutions
- Uppsala University (SE)
- Oslo University Hospital (NO)
- Karolinska University Hospital (SE)
- University of Helsinki (FI)
- University of Turku (FI)
- Tampere University (FI)
- University of Eastern Finland (FI)
- University of Southern Denmark (DK)
- Oulu University Hospital (FI)
- Helsinki University Hospital (FI)
- Haukeland University Hospital (NO)
- Odense University Hospital (DK)
- Turku University Hospital (FI)
- Karolinska Institutet (SE)
- Kuopio University Hospital (FI)
- South Karelia Central Hospital (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
- Fimlab (Finland) (FI)
- Hospital District of Helsinki and Uusimaa (FI)
- University of Bergen (NO)
- University of Oulu (FI)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1038/s44276-025-00188-5
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- Danone
- Merck KGaA
- Finska Läkaresällskapet
- Les Laboratories Pierre Fabre
- Incyte
- Cancerfonden
- Eisai
- Astellas Pharma
- Tays
- Servier
- Ipsen
- Daiichi Sankyo Europe